Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Raised to Hold at Wall Street Zen

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Sunday, Wall Street Zen reports.

Several other equities analysts also recently commented on DMRA. Wedbush reaffirmed an “outperform” rating and issued a $40.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, September 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. Jefferies Financial Group started coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They set a “buy” rating and a $50.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Finally, Guggenheim boosted their price target on Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, September 25th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $46.50.

Damora Therapeutics, Inc. Common Stock Stock Down 3.9%

Damora Therapeutics, Inc. Common Stock stock opened at $20.25 on Friday. The stock has a market cap of $1.25 billion, a P/E ratio of -6.01 and a beta of 1.43. Damora Therapeutics, Inc. Common Stock has a twelve month low of $4.95 and a twelve month high of $38.33. The company’s 50-day moving average price is $26.38 and its two-hundred day moving average price is $25.92.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.06. Equities analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

Insider Activity at Damora Therapeutics, Inc. Common Stock

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett purchased 12,500 shares of the stock in a transaction that occurred on Friday, September 25th. The shares were acquired at an average cost of $20.23 per share, with a total value of $252,875.00. Following the completion of the transaction, the chief executive officer owned 512,500 shares in the company, valued at $10,367,875. The trade was a 2.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.40% of the company’s stock.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of institutional investors have recently bought and sold shares of the business. Braidwell LP acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $42,146,000. Seven Fleet Capital Management LP bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth approximately $7,398,000. Squarepoint Ops LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth approximately $303,000. Finally, Arizona State Retirement System bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth approximately $260,000. Institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.